DJIA 16,399.67 19.26 0.12%
NASDAQ 4,316.07 57.64 1.35%
S&P 500 1,904.01 17.25 0.91%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

43.17 0.09 (0.21%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALKS $43.17 0.21%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $42.88
Previous Close $43.08
Daily Range $42.83 - $43.94
52-Week Range $34.21 - $54.25
Market Cap $6.3B
P/E Ratio -1,436.00
Dividend (Yield) $0.00 (0.0%)
Volume 596,323
Average Daily Volume 985,585
Current FY EPS -$0.25

Sector

Healthcare

Industry

Drugs

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

News & Commentary

Is Alkermes plc Stock Undervalued?

Strong science and underserved markets can fuel further gains from this delivery-focused biopharma

Bank Of America Q3 Small & Mid-Cap Biotech Preview

5 Stocks That Will See Big Selling on Huge ETF Rebalance

3 Likely Biotech Buyout Candidates

ALKS Crosses Above Key Moving Average Level

Cramer's Lightning Round - Edwards LifeSciences Is The Hottest Game In Town (9/15/14)

'Mad Money' Lightning Round: Buy, Buy, Buy St Jude Medical

First Week of October 18th Options Trading For Alkermes (ALKS)

Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog

Credit Suisseā€™s 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014

Alkermes Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Sp

Alkermes Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic

See More ALKS News...

ALKS's Top Competitors

ALKS $43.17 (0.21%)
Current stock: ALKS
AMGN $137.51 (2.86%)
Current stock: AMGN
GILD $102.21 (1.45%)
Current stock: GILD
BIIB $311.41 (1.53%)
Current stock: BIIB